This call is a companion to our Sept. 7th note which updates our August 16th report, incorporating a broad range of pharma supply chain participant feedback into our analyses of 1) the factors that account for the gap between gross and net, 2) the profit pools retained by pharma supply chain participants and 3) the financial implications of rebate safe harbor repeal and reform.
A SLIDE DECK IS AVAILABLE IN NEPHRON'S RESEARCH LIBRARY (9/7/18)
